TULARIK INC
10-Q, EX-27, 2000-11-07
COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
Previous: TULARIK INC, 10-Q, 2000-11-07
Next: NPS PHARMACEUTICALS INC, 8-K, 2000-11-07



<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5
<LEGEND>
This schedule contains summary financial information extracted from the
consolidated balance sheet, consolidated statement of operations, and
consolidated statement of cash flows included in the Company's Form 10-Q for the
period ending September 30, 2000, and is qualified in its entirety by reference
to such financial statements.
</LEGEND>
<MULTIPLIER> 1,000

<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-2000
<PERIOD-START>                             JAN-01-2000
<PERIOD-END>                               SEP-30-2000
<CASH>                                         125,009
<SECURITIES>                                   136,314
<RECEIVABLES>                                        0
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                               265,676
<PP&E>                                          34,017
<DEPRECIATION>                                  15,987
<TOTAL-ASSETS>                                 338,275
<CURRENT-LIABILITIES>                           37,441
<BONDS>                                              0
                                0
                                          0
<COMMON>                                            48
<OTHER-SE>                                     269,846
<TOTAL-LIABILITY-AND-EQUITY>                   338,275
<SALES>                                              0
<TOTAL-REVENUES>                                18,644
<CGS>                                                0
<TOTAL-COSTS>                                        0
<OTHER-EXPENSES>                                52,642
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                             (1,098)
<INCOME-PRETAX>                               (29,097)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                           (29,097)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                      (4,800)
<NET-INCOME>                                  (33,897)
<EPS-BASIC>                                     (0.73)
<EPS-DILUTED>                                   (0.73)


</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission